By continuing to browse our website, you agree to the storing of first- and third-party cookies and related technologies on your device to enhance site access and navigation, analyze site usage, authenticate users, facilitate transactions, and assist in our marketing efforts. Please read our privacy notice to learn more.
UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Paxlovid may not reduce hospitalization risk for vaccinated older adults

Washington Post

A new study suggests Paxlovid may not reduce risk of covid hospitalizations and all-cause deaths in vaccinated adults ages 65 to 74. Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests.

Paxlovid — Pfizer’s combination of nirmatrelvir and ritonavir — has been found to reduce symptoms, hospitalizations and deaths in unvaccinated, at-risk patients. However, a Pfizer trial published in 2024 found the medication didn’t significantly shorten the duration of symptoms in vaccinated adults.

Continue reading

twitter facebook bluesky email print

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.